These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22840259)

  • 1. What should drive the choice of allergen for immunotherapy in polysensitized patients?
    Ciprandi G; Incorvaia C; Puccinelli P; Dell'Albani I; Frati F
    Ann Allergy Asthma Immunol; 2012 Aug; 109(2):148-9. PubMed ID: 22840259
    [No Abstract]   [Full Text] [Related]  

  • 2. What will allergen immunotherapy look like in the future?
    Nelson HS
    Ann Allergy Asthma Immunol; 2012 Aug; 109(2):87-9. PubMed ID: 22840246
    [No Abstract]   [Full Text] [Related]  

  • 3. Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient.
    Nelson HS
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1443-1451. PubMed ID: 27687128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some highlights of the first century of immunotherapy.
    Nelson HS
    Ann Allergy Asthma Immunol; 2011 Nov; 107(5):417-21. PubMed ID: 22018612
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence.
    Calderón MA; Cox L; Casale TB; Moingeon P; Demoly P
    J Allergy Clin Immunol; 2012 Apr; 129(4):929-34. PubMed ID: 22244595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparing and mixing allergen vaccines for subcutaneous immunotherapy.
    Nelson HS
    Clin Allergy Immunol; 2008; 21():303-20. PubMed ID: 18828513
    [No Abstract]   [Full Text] [Related]  

  • 7. Anaphylaxis caused by allergen sublingual immunotherapy?
    André C; Fadel R
    Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
    [No Abstract]   [Full Text] [Related]  

  • 8. Allergen immunotherapy.
    Mannan S
    Immunotherapy; 2017 Nov; 9(15):1199-1200. PubMed ID: 29130796
    [No Abstract]   [Full Text] [Related]  

  • 9. [GUIDE TO ALLERGEN IMMUNOTHERAPY FOR MITE ALLERGY].
    Gotoh M
    Arerugi; 2017; 66(6):788-791. PubMed ID: 28701643
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
    Rossi RE; Monasterolo G; Coco G; Operti D
    Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epicutaneous immunotherapy.
    Scheurer S; Toda M
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():25-29. PubMed ID: 29108765
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of polysensitized patient: from molecular diagnostics to biomolecular immunotherapy.
    Ciprandi G; Incorvaia C; Frati F;
    Expert Rev Clin Immunol; 2015; 11(9):973-6. PubMed ID: 26144241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular-allergological aspects of allergen-specific immunotherapy].
    Jappe U
    Hautarzt; 2017 Apr; 68(4):271-281. PubMed ID: 28293695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy.
    Bauer CS; Rank MA
    J Allergy Clin Immunol; 2014 Sep; 134(3):765-765.e2. PubMed ID: 25171871
    [No Abstract]   [Full Text] [Related]  

  • 15. Allergen injection immunotherapy.
    Varga EM; Durham SR
    Clin Allergy Immunol; 2002; 16():533-49. PubMed ID: 11577558
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunotherapy, one century later.
    Passalacqua G; Bush RK
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):551-3. PubMed ID: 21971328
    [No Abstract]   [Full Text] [Related]  

  • 18. Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy.
    Weber RW
    J Allergy Clin Immunol; 2008 Jul; 122(1):219-21. PubMed ID: 18602577
    [No Abstract]   [Full Text] [Related]  

  • 19. [Allergen-specific immunotherapy or desensitization].
    Demoly P; Michel FB
    Bull Acad Natl Med; 2009 May; 193(5):1127-44; discussion 1144-5. PubMed ID: 20120392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.